Drug
Bdc 1001
Bdc 1001: highest development phase Phase 2, developed by Bolt Biotherapeutics. 2 trial records tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Bolt Biotherapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| BDC-1001 NCT05954143 | Phase 2 | Metastatic Breast Cancer |
| BDC-1001 NCT04278144 | Phase 1/2 | HER2-positive Solid Tumors |
Latest
No recent events.
Follow Bdc 1001 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.